Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J,
Corrado M (1998) Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.
J Am Med Assoc 279:125–129
Projan SJ, Novick RP (1997) The molecular basis of pathogenicity. In: Crossley KB, Archer GL
(eds) The Staphylococci in human diseases. Churchill Livingstone, New York, NY, pp 55–82
Reato G, Cuffini AM, Tullio V, Mandras N, Roana J, Banche G, Foa R, Carlone NA (2004)
Immunomodulating effect of antimicrobial agents on cytokine production by human polymor-
phonuclear neutrophils. Int J Antimicrob Agents 23:150–154
Rice KC, Bayles KW (2008) Molecular control of bacterial death and lysis. Microbiol Mol Biol
Rev 72:85–109
Rybak MJ (2006) Pharmacodynamics: Relation to antimicrobial resistance. Am J Infect Control 34
(Suppl 1):S38–S45
Safdar N, Andes D, Craig WA (2004) In vivo pharmacodynamic activity of daptomycin. Anti-
microb Agents Chemother 48:63–68
Schrag SJ, Pen ̃a C, Ferna ́ndez J, Sa ́nchez J, Go ́mez V, Pe ́rez E, Feris JM, Besser RE (2001) Effect
of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: A rando-
mized trial. J Am Med Assoc 286:49–56
Schwegmann A, Brombacher F (2008) Host-directed drug targeting of factors hijacked by patho-
gens. Sci Signal 1(29):re8
Shah PM, Zwischenbrugger H, Stille W (1976) Bactericidal dose–activity relationships with
E. coli, K. pneumoniaeand S. aureus(author’s translation). Dtsch Med Wochenschr
101:325–328
Shryock TR, Mortensen JE, Baumholtz M (1998) The effects of macrolides on the expression of
bacterial virulence mechanisms. J Antimicrob Chemother 41:505–512
Siegel RE (2008) Emerging gram-negative antibiotic resistance: daunting challenges, declining
sensitivities, and dire consequences. Respir Care 53:471–479
Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J (2005) Inhibition of daptomycin by
pulmonary surfactant: In vitro modeling and clinical impact. J Infect Dis 191:2149–2152
Simjee S, Silley P, Werling HO, Bywater R (2008) Potential confusion regarding the term
‘resistance’ in epidemiological surveys. J Antimicrob Chemother 61:228–229
Slocombe RF, Malark J, Ingersoll R, Derksen JF, Robinson NE (1985) Importance of neutrophils
in the pathogenesis of acute pneumonia pasteurellosis in calves. Am J Vet Res 46:2253–2258
Smith K, Perez A, Ramage G, Gemmell CG, Lang S (2009) Comparison of biofilm-associated cell
survival following in vitro exposure of meticillin-resistantStaphylococcus aureusbiofilms to
the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin. Int J Anti-
microb Agents 33:374–378
Soto SM, Smithson A, Horcajada JP, Martinez JA, Mensa JP, Vila J (2006) Implication of biofilm
formation in the persistence of urinary tract infection caused by uropathogenic Escherichia
coli. Clin Microbiol Infect 12:1034–1036
Steenbergen JN, Alder J, Thorne GM, Tally FP (2005) Daptomycin: A lipopeptide antibiotic for
the treatment of serious Gram-positive infections. J Antimicrob Chemother 55:283–288
Stein RA (2008) When less is more: High-dose, short duration regimens and antibiotic resistance.
Int J Clin Pract 62:1304–1305
Sung JM, Chantler PD, Lloyd DH (2006) Accessory gene regulator locus of Staphylococcus
intermedius. Infect Immun 74:2947–2956
Tam VA, Louie A, Fritsche TR, Deziel M, Liu W, Brown DL, Deshpande L, Leary R, Jones RN,
Drusano GL (2007) Impact of drug-exposure intensity and duration of therapy on the
emergence ofStaphylococcus aureusresistance to a quinolone antimicrobial. J Infect Dis
195:1818–1827
Tanaka G, Shigeta M, Komatsuzawa H, Sugai M, Suginaka H, Usui T (1999) Effect of the growth
rate of Pseudomonas aeruginosa biofilms on the susceptibility to antimicrobial agents: Beta-
lactams and fluoroquinolones. Chemotherapy 45:28–36
Antimicrobial Drug Resistance 263